Molly W Mandernach, MD, MPH
Associate Professor
About Molly W Mandernach
Dr. Mandernach is a Clinical Associate Professor of Medicine within the division of hematology and oncology, and serves as a clinician educator with a focus on thrombosis and hemostasis and sickle cell disease. She is a member of the American Society of Hematology.
Teaching Profile
Courses Taught
2020-2023
PAS5010 Intro to Medicine 1
2020-2024
BMS6631 Hematology
2018
MDC7200 Medicine Clerkship
2018
MDC6001 Intro Clin Practice
Board Certifications
-
HematologyAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
-
OncologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Cancer
- Hematology
- Hematology and Oncology
Areas of Interest
- Deep vein thrombosis
- Sickle cell disease
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-8793-9747
Publications
2023
Hybrid effectiveness-implementation trial of guided relaxation and acupuncture for chronic sickle cell disease pain (GRACE): A protocol.
Contemporary clinical trials communications.
32
[DOI] 10.1016/j.conctc.2023.101076.
[PMID] 36852100.
2023
Impact of genotype on clinical course in sickle cell disease and the utility of neutrophil-lymphocyte ratio: a ten-year single-institution experience.
Expert review of hematology.
16(9):701-710
[DOI] 10.1080/17474086.2023.2231637.
[PMID] 37395002.
2023
Monitoring and responding to signals of suicidal ideation in pragmatic clinical trials: Lessons from the GRACE trial for Chronic Sickle Cell Disease Pain
Contemporary Clinical Trials Communications.
36
[DOI] 10.1016/j.conctc.2023.101218.
[PMID] 37842321.
2022
A Stress and Pain Self-management mHealth App for Adult Outpatients With Sickle Cell Disease: Protocol for a Randomized Controlled Study
JMIR Research Protocols.
11(7)
[DOI] 10.2196/33818.
[PMID] 35904878.
2022
Multidisciplinary Management of a Hemophilia A Patient Requiring Coronary Artery Bypass Graft Surgery.
Journal of cardiothoracic and vascular anesthesia.
36(2):534-538
[DOI] 10.1053/j.jvca.2021.10.029.
[PMID] 34895963.
2022
Nursing Education for the Acute Care Nurse on Pain Mechanisms of Sickle Cell Disease.
Journal of continuing education in nursing.
53(3):137-144
[DOI] 10.3928/00220124-20220210-09.
[PMID] 35244458.
2021
Acquired von Willebrand syndrome in association with multiple myeloma: remission after stem cell transplant.
BMJ case reports.
14(1)
[DOI] 10.1136/bcr-2020-239053.
[PMID] 33504531.
2021
Reflections of Healthcare Experiences of African Americans With Sickle Cell Disease or Cancer: A Qualitative Study.
Cancer nursing.
44(1):E53-E61
[DOI] 10.1097/NCC.0000000000000750.
[PMID] 31743153.
2020
Randomized Pilot Study: A Mobile Technology-based Self-management Intervention for Sickle Cell Pain.
Western journal of nursing research.
42(8):629-639
[DOI] 10.1177/0193945919878821.
[PMID] 31583977.
2019
Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.
Transfusion.
59(6):1907-1910
[DOI] 10.1111/trf.15198.
[PMID] 30768787.
2019
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
BMJ case reports.
12(3)
[DOI] 10.1136/bcr-2018-224636.
[PMID] 30872333.
2019
Pre-operative therapeutic plasma Exchange and intravenous immune globulin for the treatment of heparin induced thrombocytopenia in a lung transplant recipient
Transfusion and Apheresis Science.
58(4):505-507
[DOI] 10.1016/j.transci.2019.05.010.
2019
Severe Case of Plasmodium falciparum Malaria in a Pregnant Woman from Nigeria.
Case reports in infectious diseases.
2019
[DOI] 10.1155/2019/2630825.
[PMID] 31772792.
2018
The Effects of Relaxation Intervention on Pain, Stress, and Autonomic Responses among Adults with Sickle Cell Pain in the Outpatient Setting
Journal of Pain.
19(3)
2017
Coping with Pain in the Face of Healthcare Injustice in Patients with Sickle Cell Disease.
Journal of immigrant and minority health.
19(6):1449-1456
[DOI] 10.1007/s10903-016-0432-0.
[PMID] 27215766.
2015
Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review.
Therapeutics and clinical risk management.
11:1273-82
[DOI] 10.2147/TCRM.S68010.
[PMID] 26345156.
2012
Effectiveness of Standardized Venous Thromboembolism Prophylaxis Order Sets in Patients Undergoing Abdominal Or Pelvic Surgery for Cancer
Blood.
120
2007
Chronic oral anticoagulant therapy for extrahepatic visceral thrombosis is safe.
Journal of thrombosis and thrombolysis.
23(3):223-8
[PMID] 17221331.
Grants
May 2022
ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Sep 2021
ACTIVE
Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain
Role: Co-Investigator
Funding: UNIV OF ILLINOIS CHICAGO
via NATL INST OF HLTH NCI
Sep 2021
ACTIVE
Education and Mentoring to Bring Access to Comprehensive Care (EMBRACE) Network
Role: Principal Investigator
Funding: UNIV OF ALABAMA BIRMINGHAM
via US HLTH RESOURCES AND SERV ADMN
Sep 2020
– Aug 2021
Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain
Role: Co-Investigator
Funding: UNIV OF ILLINOIS CHICAGO
via NATL INST OF HLTH NINDS
Sep 2020
ACTIVE
A Stress and Pain Self-management m-Health App for Adult Outpatients with Sickle Cell Disease
Role: Co-Investigator
Funding: NATL INST OF HLTH NINR
Dec 2019
– Aug 2022
A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients = 16 years with chronic kidney
disease due to sickle cell nephropathy (STEADFAST)
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Sep 2017
– Jul 2022
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease
Role: Principal Investigator
Funding: GLOBAL BLOOD THERAPEUTICS
Education
Fellowship – Hematology Oncology
2012
·
University of Florida
Residency – Internal Medicine
2008
·
University of Florida
Medical Degree
2005
·
University of Florida
Master of Public Health
2001
·
University of South Florida
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- mweidner@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD
GAINESVILLE FL 32610